| Year |
Citation |
Score |
| 2006 |
Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, Hicklin DJ. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. International Journal of Cancer. 119: 1519-29. PMID 16671089 DOI: 10.1002/Ijc.21865 |
0.337 |
|
| 2005 |
Miller DW, Vosseler S, Mirancea N, Hicklin DJ, Bohlen P, Völcker HE, Holz FG, Fusenig NE. Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. The American Journal of Pathology. 167: 1389-403. PMID 16251423 DOI: 10.1016/S0002-9440(10)61226-6 |
0.341 |
|
| 2005 |
Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. The Journal of Clinical Investigation. 115: 2992-3006. PMID 16224539 DOI: 10.1172/Jci24586 |
0.301 |
|
| 2005 |
Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Fillbrandt R, Westphal M. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4934-40. PMID 16000592 DOI: 10.1158/1078-0432.CCR-04-2270 |
0.377 |
|
| 2005 |
Vincent L, Jin DK, Karajannis MA, Shido K, Hooper AT, Rashbaum WK, Pytowski B, Wu Y, Hicklin DJ, Zhu Z, Bohlen P, Niesvizky R, Rafii S. Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells. Cancer Research. 65: 3185-92. PMID 15833849 DOI: 10.1158/0008-5472.Can-04-3598 |
0.344 |
|
| 2005 |
Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, Rolser R, Malikzay A, Persaud A, Corcoran E, Deevi DS, Balderes P, Bassi R, Jimenez X, Joynes CJ, ... ... Bohlen P, et al. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Molecular Cancer Therapeutics. 4: 369-79. PMID 15767546 DOI: 10.1158/1535-7163.MCT-04-0114 |
0.31 |
|
| 2005 |
Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity Journal of Biological Chemistry. 280: 19665-19672. PMID 15757893 DOI: 10.1074/jbc.M500815200 |
0.328 |
|
| 2005 |
Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Research. 65: 1294-305. PMID 15735015 DOI: 10.1158/0008-5472.CAN-03-3986 |
0.326 |
|
| 2005 |
May C, Doody JF, Abdullah R, Balderes P, Xu X, Chen CP, Zhu Z, Shapiro L, Kussie P, Hicklin DJ, Liao F, Bohlen P. Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature. Blood. 105: 4337-44. PMID 15701713 DOI: 10.1182/Blood-2005-01-0010 |
0.314 |
|
| 2005 |
Pauli SA, Tang H, Wang J, Bohlen P, Posser R, Hartman T, Sauer MV, Kitajewski J, Zimmermann RC. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology. 146: 1301-11. PMID 15591152 DOI: 10.1210/en.2004-0765 |
0.317 |
|
| 2005 |
Nakhuda GS, Zimmermann RC, Bohlen P, Liao F, Sauer MV, Kitajewski J. Inhibition of the vascular endothelial cell (VE)-specific adhesion molecule VE-cadherin blocks gonadotropin-dependent folliculogenesis and corpus luteum formation and angiogenesis. Endocrinology. 146: 1053-9. PMID 15591148 DOI: 10.1210/En.2004-0977 |
0.367 |
|
| 2004 |
Zhang H, Li Y, Li H, Bassi R, Jimenez X, Witte L, Bohlen P, Hicklin D, Zhu Z. Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2. Leukemia & Lymphoma. 45: 1887-97. PMID 15223651 DOI: 10.1080/10428190410001712225 |
0.352 |
|
| 2004 |
Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L, Zhu Z. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. The Journal of Biological Chemistry. 279: 2856-65. PMID 14576153 DOI: 10.1074/jbc.M310132200 |
0.334 |
|
| 2003 |
De Bandt M, Ben Mahdi MH, Ollivier V, Grossin M, Dupuis M, Gaudry M, Bohlen P, Lipson KE, Rice A, Wu Y, Gougerot-Pocidalo MA, Pasquier C. Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. Journal of Immunology (Baltimore, Md. : 1950). 171: 4853-9. PMID 14568965 |
0.329 |
|
| 2003 |
Zimmermann RC, Hartman T, Kavic S, Pauli SA, Bohlen P, Sauer MV, Kitajewski J. Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development. The Journal of Clinical Investigation. 112: 659-69. PMID 12952915 DOI: 10.1172/JCI18740 |
0.31 |
|
| 2003 |
Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. The Journal of Biological Chemistry. 278: 43496-507. PMID 12917408 DOI: 10.1074/jbc.M307742200 |
0.335 |
|
| 2003 |
Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, Liu M, Tejada R, Friedrich M, Bohlen P, Witte L, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia. 17: 604-11. PMID 12646950 DOI: 10.1038/Sj.Leu.2402831 |
0.387 |
|
| 2002 |
Zhu Z, Bohlen P, Witte L. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Current Cancer Drug Targets. 2: 135-56. PMID 12188915 |
0.344 |
|
| 2002 |
Corada M, Zanetta L, Orsenigo F, Breviario F, Lampugnani MG, Bernasconi S, Liao F, Hicklin DJ, Bohlen P, Dejana E. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood. 100: 905-11. PMID 12130501 |
0.345 |
|
| 2002 |
Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Medicine. 8: 831-40. PMID 12091877 DOI: 10.1038/nm731 |
0.348 |
|
| 2002 |
Zimmermann RC, Xiao E, Bohlen P, Ferin M. Administration of antivascular endothelial growth factor receptor 2 antibody in the early follicular phase delays follicular selection and development in the rhesus monkey Endocrinology. 143: 2496-2502. PMID 12072380 DOI: 10.1210/en.143.7.2496 |
0.31 |
|
| 2002 |
Liao F, Doody JF, Overholser J, Finnerty B, Bassi R, Wu Y, Dejana E, Kussie P, Bohlen P, Hicklin DJ. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability Cancer Research. 62: 2567-2575. PMID 11980651 |
0.352 |
|
| 2002 |
Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. International Journal of Cancer. 97: 393-9. PMID 11774295 DOI: 10.1002/ijc.1634 |
0.375 |
|
| 2001 |
Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA, Rafii S. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proceedings of the National Academy of Sciences of the United States of America. 98: 10857-62. PMID 11553814 DOI: 10.1073/Pnas.191117498 |
0.357 |
|
| 2000 |
Lu D, Kussie P, Pytowski B, Persaud K, Bohlen P, Witte L, Zhu Z. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. The Journal of Biological Chemistry. 275: 14321-30. PMID 10799512 DOI: 10.1074/JBC.275.19.14321 |
0.33 |
|
| 1999 |
Lu D, Kotanides H, Jimenez X, Zhou Q, Persaud K, Bohlen P, Witte L, Zhu Z. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2 Journal of Immunological Methods. 230: 159-171. PMID 10594363 DOI: 10.1016/S0022-1759(99)00135-0 |
0.351 |
|
| 1999 |
Zhu Z, Lu D, Kotanides H, Santiago A, Jimenez X, Simcox T, Hicklin DJ, Bohlen P, Witte L. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Letters. 136: 203-13. PMID 10355750 DOI: 10.1016/S0304-3835(98)00324-3 |
0.387 |
|
| Show low-probability matches. |